14. December 2021.
Hemofarm, which operates within STADA Group, has undertaken to distribute and market the portfolio of the Consumer Healthcare brands of the company Sanofi, thereby further expanding the offer of medicines to patients and consumers in Serbia. Bisolvon, Buscopan and Dulcolax are just some of the well-established brands covered by the agreement between STADA and Sanofi, that will be available in Serbia through Hemofarm.
In the middle of this year, STADA and Sanofi have concluded an agreement covering 20 European countries, with Serbia among them, based on which STADA will be in charge of distribution and marketing of the Sanofi’s portfolio in these markets. The agreement between the two multinationals encompasses the distribution of approximately 50 Sanofi brands, including cough and cold relief products, anti-allergy products, pain relief products, products for improving the function of digestive organs, dietary supplements, etc. Eleven products within seven brands, including Buscopan, Bisolvon, Dulcolax, Essentiale Forte, etc. will be available in the Serbian market.
According to Hemofarm Chief Executive Officer Ronald Seeliger, this company confirms every day how important a partner it is to patients and consumers in Serbia, as well as to the entire healthcare system, because it constantly expands the portfolio of products, invests in its modernization, and strives to respond to every disease and health problem by adequate medicine and prevention.
‘Our extensive portfolio of medicines and medical devices is the response of profession and science to numerous diseases and health problems of patients through modern pharmaceutical solutions. By adding new brands such as Bisolvon, Buscopan and Dulcolax, Hemofarm confirms how reliable a partner it is to doctors, pharmacists, patients, and consumers across the country, as it offers modern solutions for different health problems of people’, CEO Seeliger pointed out.
In this way Hemofarm expands the existing portfolio of brands for cough, cold and respiratory diseases relief, as well as digestive health category and the existing range of products for tackling allergic reactions.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 713.3 million. As of 31 December 2020, STADA employed 12,301 people worldwide.
